Automate Your Wheel Strategy on ILMN
With Tiblio's Option Bot, you can configure your own wheel strategy including ILMN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ILMN
- Rev/Share 27.1139
- Book/Share 16.4937
- PB 5.758
- Debt/Equity 0.9666
- CurrentRatio 1.8077
- ROIC 0.2209
- MktCap 14596889000.0
- FreeCF/Share 6.5253
- PFCF 14.158
- PE 11.9279
- Debt/Assets 0.4138
- DivYield 0
- ROE 0.5312
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ILMN | Daiwa Securities | Outperform | Neutral | -- | $94 | Aug. 12, 2025 |
| Downgrade | ILMN | Scotiabank | Sector Outperform | Sector Perform | -- | $125 | July 11, 2025 |
| Reiterated | ILMN | Citigroup | -- | Neutral | $130 | $90 | March 4, 2025 |
| Downgrade | ILMN | HSBC Securities | Buy | Hold | -- | $100 | Feb. 28, 2025 |
| Downgrade | ILMN | Barclays | Equal Weight | Underweight | $130 | $100 | Feb. 10, 2025 |
| Downgrade | ILMN | TD Cowen | Buy | Hold | $177 | $140 | Feb. 7, 2025 |
| Downgrade | ILMN | Citigroup | Buy | Neutral | $190 | $165 | Dec. 11, 2024 |
| Upgrade | ILMN | HSBC Securities | Hold | Buy | -- | $180 | Oct. 17, 2024 |
| Upgrade | ILMN | Argus | Hold | Buy | -- | -- | Aug. 28, 2024 |
| Upgrade | ILMN | Daiwa Securities | Neutral | Buy | $120 | $154 | Aug. 16, 2024 |
News
Illumina launches new business to accelerate technology and data-driven discovery
Published: October 01, 2025 by: PRNewsWire
Sentiment: Neutral
New business focuses on developing data assets, software, and AI to fuel life science breakthroughs Expands pharma access to large omics datasets to advance target discovery and drug development SAN DIEGO , Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic insights driven by the need of researchers and pharma companies to access and interpret ever larger-scale multiomic data. By bringing together Illumina's strengths across sequencing, data analysis, software and AI, BioInsight will empower customers and partners with solutions to identify …
Read More
KMDA vs. ILMN: Which Stock Is the Better Value Option?
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Kamada (KMDA) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now?
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors are showing growing interest in the rapidly expanding Precision Oncology market, which is expected to witness a compound annual growth rate (CAGR) of 8% between 2025 and 2030, according to Grand View Research. Tempus AI TEM and Illumina ILMN are two key players with significant presence in this market.
Read More
ILMN Stock vs. IQV Stock
Published: September 26, 2025 by: Forbes
Sentiment: Negative
Amid increased competition from China's MGI Tech, Illumina's stock (NASDAQ: ILMN) has dropped by 11% in a week. MGI Tech's DNA sequencers are reportedly gaining market share, and despite a recent decline in its international sales due to U.S. sanctions, MGI Tech's global market presence remains strong.
Read More
Here's Why Illumina (ILMN) is a Strong Momentum Stock
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Illumina advances personalized cancer care with new pharma development partnerships
Published: September 23, 2025 by: PRNewsWire
Sentiment: Neutral
Illumina and pharma partners will develop companion diagnostics for historically important KRAS biomarker SAN DIEGO , Sept. 23, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) will partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TruSight™ Oncology (TSO) Comprehensive genomic profiling test.
Read More
Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine
Published: September 18, 2025 by: PRNewsWire
Sentiment: Neutral
Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people SAN DIEGO , Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) (Alnylam) as a member of the Alliance for Genomic Discovery (AGD).
Read More
ILMN Stock to Gain From the Launch of Illumina Protein Prep Assay
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The Illumina Protein Prep rollout boosts multiomics, strengthens disease insights and supports ILMN stock momentum.
Read More
Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development
Published: September 03, 2025 by: PRNewsWire
Sentiment: Neutral
Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease Following early access program, customers commend scale, high consistency, and easy sample to insights workflow Launch follows Illumina's announcement of agreement to acquire SomaLogic SAN DIEGO , Sept. 3, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of Illumina Protein Prep, an assay introducing superior performance for next-generation sequencing (NGS) based proteomics discovery at scale.
Read More
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
KMDA vs. ILMN: Which Stock Is the Better Value Option?
Published: August 14, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Illumina (ILMN) Reliance on International Sales: What Investors Need to Know
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Evaluate Illumina's (ILMN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Read More
These Analysts Boost Their Forecasts On Illumina Following Upbeat Results
Published: August 01, 2025 by: Benzinga
Sentiment: Positive
Illumina, Inc. ILMN reported better-than-expected earnings for the second quarter on Thursday.
Read More
Gear Up for Illumina (ILMN) Q2 Earnings: Wall Street Estimates for Key Metrics
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Illumina (ILMN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Read More
Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling
Published: July 30, 2025 by: PRNewsWire
Sentiment: Neutral
Illumina TruSight™ Oncology 500 v2 research assay is now available with built-in HRD biomarker detection, faster turnaround time, and lower tissue sample input Illumina's growing research and clinical oncology portfolio broadens access to critical biomarker testing SAN DIEGO , July 30, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of the next generation of TruSight Oncology 500, its flagship cancer research assay that enables comprehensive genomic profiling. Comprehensive genomic profiling (CGP) is a critical tool to accelerate access to precision medicine by providing a molecular tumor profile to labs advancing research in therapy selection and clinical trial …
Read More
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
HRMY vs. ILMN: Which Stock Should Value Investors Buy Now?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Illumina named to TIME's World's Most Sustainable Companies list for the second consecutive year
Published: July 10, 2025 by: PRNewsWire
Sentiment: Neutral
Illumina was also recognized as one of the Best Companies to Work For byU.S. News & World Report SAN DIEGO , July 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced two awards recognizing the company's leadership in sustainability practices and as an employer of choice. TIME named Illumina to its World's Most Sustainable Companies list for the second year in a row, and U.S. News & World Report named Illumina to its Best Companies to Work For list.
Read More
Illumina Stock May Benefit From New Agreement to Acquire SomaLogic
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Positive
ILMN jumps 2.9% after striking a $350M deal to acquire SomaLogic and boost its fast-growing multiomics strategy.
Read More
Cathie Wood Is Dumpster Diving Again With These 3 Stock Buys
Published: June 25, 2025 by: 24/7 Wall Street
Sentiment: Positive
Key Points in This Article: Cathie Wood's ARK Innovation ETF (ARKK) has seen a mixed performance over the past five years, reflecting her high-risk, high-reward focus on disruptive technologies to prosper over time.
Read More
Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral
Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO , June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based …
Read More
FTRE vs. ILMN: Which Stock Should Value Investors Buy Now?
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
ILMN unveils PromoterAI to decode noncoding genetic variants, aiming to drive breakthroughs in rare disease diagnosis.
Read More
Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis
Published: May 29, 2025 by: PRNewsWire
Sentiment: Neutral
New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time SAN DIEGO , May 29, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. A study published today in Science illustrates how this deep learning technology discovered regulatory variants in noncoding "promoter" segments that contribute up to 6% of the genetic causes of rare diseases.
Read More
Illumina's TSO Comprehensive Earns Japan's Approval: Stock to Gain?
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Japan approves ILMN's TSO Comprehensive, marking a key step forward in global precision oncology adoption and clinical use.
Read More
Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies
Published: May 28, 2025 by: PRNewsWire
Sentiment: Neutral
Following FDA approval last year, Illumina's TSO Comprehensive test gains broad payer reimbursement, expanding access to comprehensive genomic profiling to match patients with targeted therapies Illumina's IVD portfolio will also expand to offer Pillar oncoReveal® CDx, the newest panel to deliver critical companion diagnostic testing using the Illumina MiSeq™ Dx System SAN DIEGO , May 28, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced an expanded clinical oncology portfolio, unlocking the next new solutions to advance precision oncology and improve the standard of care. The company's broad range of clinical offerings will accelerate access to precision oncology for more …
Read More
Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive
ILMN's latest software features easy-to-use oncology apps, enhanced multiomics pipelines and AWS F2 support, enabling faster turnaround times.
Read More
Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry's Largest NGS-Based Proteomics Panel
Published: May 19, 2025 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif.--(BUSINESS WIRE)--Signios Biosciences (“Signios Bio”), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina, announced today an Illumina-sponsored grant for Early Access to Illumina Protein Prep 9.5K™. Powered by SOMAmer® technology, this next-generation sequencing (NGS)-based platform enables comprehensive proteomic profiling of plasma and serum. Illumina Protein Prep 9.5K™ utilizes slow off-rate modified.
Read More
Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications
Published: May 13, 2025 by: PRNewsWire
Sentiment: Neutral
Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling New features include easy-to-use oncology apps, enhanced multiomics pipelines, and AWS F2 support enabling faster turnaround times SAN DIEGO , May 13, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of DRAGEN™ version 4.4 software (v4.4), the industry's most comprehensive secondary analysis solution. The latest version of DRAGEN includes out-of-the-box oncology applications for clinical research and support for newly announced Illumina multiomics assays.
Read More
Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications
Published: May 13, 2025 by: PRNewsWire
Sentiment: Neutral
Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling New features include easy-to-use oncology apps, enhanced multiomics pipelines, and AWS F2 support enabling faster turnaround times SAN DIEGO , May 13, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of DRAGEN™ version 4.4 software (v4.4), the industry's most comprehensive secondary analysis solution. The latest version of DRAGEN includes out-of-the-box oncology applications for clinical research and support for newly announced Illumina multiomics assays.
Read More
About Illumina, Inc. (ILMN)
- IPO Date 2000-07-28
- Website https://www.illumina.com
- Industry Medical - Diagnostics & Research
- CEO Jacob Thaysen
- Employees 8970